Is Krystal Biotech, Inc. overvalued or undervalued?

As of 7 November 2025, the valuation grade for Krystal Biotech, Inc. moved from expensive to fair. This suggests that the stock is currently fairly valued. Key valuation ratios include a P/E ratio of 27, an EV to EBITDA ratio of 23.83, and a PEG ratio of 0.25, indicating a strong growth potential relative to its price.
In comparison to its peers, Krystal Biotech's P/E ratio is higher than that of Halozyme Therapeutics, Inc., which has a P/E of 15.92, and significantly above Elanco Animal Health, Inc. at 19.25. Despite this, the company has demonstrated robust performance with a year-to-date return of 27.36%, significantly outpacing the S&P 500's return of 14.40% over the same period, reinforcing the notion that the stock is positioned well in the market.